| Dr Eric Bret Baud, MD | |
|
5 Severance Cir, Suite 205, Cleveland Heights, OH 44118-1566 | |
| (216) 382-7072 | |
| (216) 691-3944 |
| Full Name | Dr Eric Bret Baud |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 32 Years |
| Location | 5 Severance Cir, Cleveland Heights, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265431654 | NPI | - | NPPES |
| 070011004 | Other | OH | MEDICARE RAILROAD |
| 0281501 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35065990 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Dermatology Group Llc | 0446579833 | 2 |
News Archive
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
More than 5 million Americans today are affected by Alzheimer's disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million people with AD worldwide by 2050.
"With the HIV prevalence rate higher among women than men in Zambia, experts say the epidemic now has a women's face here and, therefore, requires more specialized intervention programs," and "women living with HIV say that women must be taught how to live positively with it," the Global Press Institute reports in a story examining the epidemic among women in Zambia.
Neurodegeneration in ALS/FTD may be caused by TDP-43 aggregation in the cytoplasm, causing cellular traffic jams. The trial drug can sequester TDP-43.
› Verified 3 days ago
| Entity Name | Cleveland Dermatology Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407249071 PECOS PAC ID: 0446579833 Enrollment ID: O20150506002485 |
News Archive
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
More than 5 million Americans today are affected by Alzheimer's disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million people with AD worldwide by 2050.
"With the HIV prevalence rate higher among women than men in Zambia, experts say the epidemic now has a women's face here and, therefore, requires more specialized intervention programs," and "women living with HIV say that women must be taught how to live positively with it," the Global Press Institute reports in a story examining the epidemic among women in Zambia.
Neurodegeneration in ALS/FTD may be caused by TDP-43 aggregation in the cytoplasm, causing cellular traffic jams. The trial drug can sequester TDP-43.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Bret Baud, MD 2248 Coventry Rd, Cleveland Heights, OH 44118-3547 Ph: () - | Dr Eric Bret Baud, MD 5 Severance Cir, Suite 205, Cleveland Heights, OH 44118-1566 Ph: (216) 382-7072 |
News Archive
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
More than 5 million Americans today are affected by Alzheimer's disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million people with AD worldwide by 2050.
"With the HIV prevalence rate higher among women than men in Zambia, experts say the epidemic now has a women's face here and, therefore, requires more specialized intervention programs," and "women living with HIV say that women must be taught how to live positively with it," the Global Press Institute reports in a story examining the epidemic among women in Zambia.
Neurodegeneration in ALS/FTD may be caused by TDP-43 aggregation in the cytoplasm, causing cellular traffic jams. The trial drug can sequester TDP-43.
› Verified 3 days ago
Dr. Vernon Eugene Sackman, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 10 Severance Cir, Cleveland Heights, OH 44118 Phone: 216-621-5600 Fax: 216-479-5554 | |
Cecelia Lynn Hamilton, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5 Severance Cir, Suite 205, Cleveland Heights, OH 44118 Phone: 216-382-7072 Fax: 216-691-3944 |